866-997-4948 (US-Canada Toll Free)

Established in 2001, the Assessment Group is the market leader in clinical practice pattern assessments of healthcare professionals, and in measuring the impact of messages on their performance. Our scientifically-validated methods and research techniques make us unique and allows to provide comprehensive clinical analytics for optimizing initiatives, demonstrating value, and ultimately...

Show More

Established in 2001, the Assessment Group is the market leader in clinical practice pattern assessments of healthcare professionals, and in measuring the impact of messages on their performance. Our scientifically-validated methods and research techniques make us unique and allows to provide comprehensive clinical analytics for optimizing initiatives, demonstrating value, and ultimately enhancing patient health.

Show Less
  • US Market Changes in the Treatment of Advanced Prostate Cancer

    Sep 2012

    By Assessment Group

    Healthcare

    30 Pages

    Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and...

    USD 2900View Report
  • US Market Changes in the Treatment of Non-Hodgkin's Lymphoma

    Sep 2012

    By Assessment Group

    Healthcare

    46 Pages

    The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkins lymphoma. A survey with unfolding patient case scenarios was presented to 158 U.S. oncologists for their open-ended responses to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal...

    USD 2900View Report
  • US Market Changes in the Treatment of Advanced Melanoma

    Sep 2012

    By Assessment Group

    Healthcare

    31 Pages

    Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the factors that influence those decisions. Data presented includes oncologist treatment regimen choices, factors that influence their decisions, barriers to optimal patient care and confidence in patient...

    USD 2900View Report
  • US Market Changes in the Treatment of Advanced Breast Cancer

    Sep 2012

    By Assessment Group

    Breast Cancer

    34 Pages

    A survey with unfolding patient case scenarios was presented to 180 U.S. oncologists who manage patients with metastatic breast cancer for their open-ended responses. In each case, oncologists were asked to respond to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and...

    USD 2900View Report
  • US Market Changes in the Treatment of Advanced Lung Cancer

    Sep 2012

    By Assessment Group

    Healthcare

    40 Pages

    The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal practice patterns of oncologists. Progressively unfolding patient case scenarios were presented to 152 U.S. oncologists for their responses to open-ended questions concerning their choices of treatment regimens, factors that influence...

    USD 2900View Report
  • Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers

    Oct 2011

    By Assessment Group

    Pharmaceutical

    27 Pages

    Understand current practice patterns related to bone metastases in patients with advanced cancers. Patient specific unfolding case scenarios presented to 174 high-prescribing oncologists on the treatment of bones metastases in patients with advanced stages of cancer including breast, renal cell carcinoma, and prostate. The survey was presented for their responses on clinical...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma

    Apr 2011

    By Assessment Group

    Pharmaceutical

    28 Pages

    Patient specific case scenario on advanced non-Hodgkin’s lymphoma in a situation involving a patient with Stage IIIA Asymptomatic Indolent Lymphoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:   Decisions in treatment and tests through disease...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma

    Apr 2011

    By Assessment Group

    Pharmaceutical

    35 Pages

    Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:  ...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

    Apr 2011

    By Assessment Group

    Pharmaceutical

    26 Pages

    A patient specific case scenario on advanced non-Hodgkin’s lymphoma involving a patient with stage IV follicular B-cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:   Decisions in treatment and tests through disease stages Factors influencing...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma

    Apr 2011

    By Assessment Group

    Pharmaceutical

    61 Pages

    Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their...

    USD 8900View Report
  • Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

    Apr 2011

    By Assessment Group

    Pharmaceutical

    25 Pages

    A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:   Decisions in treatment and tests through disease stages Factors influencing their decisions...

    USD 2999View Report
  • Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

    Apr 2011

    By Assessment Group

    Pharmaceutical

    33 Pages

    A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:   Decisions in treatment and tests through disease stages Factors...

    USD 2999View Report
  • Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

    Apr 2011

    By Assessment Group

    Pharmaceutical

    28 Pages

    A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:   Decisions in treatment and tests through disease stages...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer

    Apr 2011

    By Assessment Group

    Pharmaceutical

    56 Pages

    Experience real patient situations that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides...

    USD 8900View Report
  • Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

    Mar 2011

    By Assessment Group

    Pharmaceutical

    35 Pages

    Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.  This primary research...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer

    Mar 2011

    By Assessment Group

    Pharmaceutical

    52 Pages

    Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the...

    USD 8900View Report
  • Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey

    Mar 2011

    By Assessment Group

    Oncology

    24 Pages

    Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.  This primary research...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

    Feb 2011

    By Assessment Group

    Pharmaceutical

    42 Pages

    Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced...

    USD 6900View Report
  • Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

    Jan 2011

    By Assessment Group

    Pharmaceutical

    36 Pages

    Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions.  Patient progression reveals: Decisions in treatment throughout patient stages Factors influencing their decisions...

    USD 2999View Report
  • Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

    Jan 2011

    By Assessment Group

    Pharmaceutical

    30 Pages

    Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on specific clinical decisions.  Patient progression reveals: Decisions in treatment throughout patient stages Factors influencing their decisions...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

    Jan 2011

    By Assessment Group

    Pharmaceutical

    31 Pages

    Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing...

    USD 2999View Report
  • US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

    Jan 2011

    By Assessment Group

    Pharmaceutical

    59 Pages

    Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced...

    USD 8900View Report